New blood test tracks progression of Alzheimer’s disease
Researchers unveil a new blood test that measures Alzheimer’s progression in the brain, announced at a major clinical trials conference in Boston.
New biomarkers for Alzheimer's disease, depression, and other disorders hold promise for enhancing clinicians' abilities to diagnose and treat nervous system conditions, as presented at Neuroscience 2026. These biological markers could improve diagnosis and treatment of neurological and psychiatric disorders, which affect billions of people worldwide and cause significant disability.
Researchers are developing biomarkers from various sources, including brain imaging measures, blood substances, genetic changes, and subtle motor signs that might not be visible to the naked eye. The NINDS Translational Biomarker Program emphasizes that biomarkers and outcome assessments are crucial for better diagnosis, prognosis, disease progression monitoring, and treatment response.
Abstracts at the conference showcase how research into biomarkers and outcome assessments is expanding our understanding of mood disorders, neurodevelopmental conditions, neurodegenerative diseases, and healthy cognitive aging. For instance, brain volumes beyond the hippocampus may indicate early Alzheimer's neurodegeneration, while elevated blood biomarkers can coexist with preserved brain structure.
Mitochondrial gene changes linked to depression suggest potential biomarkers and treatment targets, and AI has identified subtle motor signs in nonhuman primate models of brain disorders.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.